Statements (78)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
gptkb:oppression |
| gptkbp:administration_guidelines |
follow healthcare provider instructions
|
| gptkbp:administration_timing |
before chemotherapy administration
|
| gptkbp:approves |
chemotherapy-induced nausea and vomiting
|
| gptkbp:availability |
available in hospitals and clinics
|
| gptkbp:class |
antiemetics
NK1 receptor antagonist |
| gptkbp:clinical_trial |
Phase 3
Phase III trials ongoing for new formulations Phase II and III completed prevention of nausea and vomiting |
| gptkbp:clinical_use |
prevent nausea and vomiting
|
| gptkbp:collaborations |
with cancer treatment centers
|
| gptkbp:community_health |
important for prescribing
|
| gptkbp:competitors |
Emend
Akynzeo Zofran |
| gptkbp:contraindication |
hypersensitivity to aprepitant or any component of the formulation
|
| gptkbp:developed_by |
Heron Therapeutics
|
| gptkbp:dosage_form |
injection
solution for infusion |
| gptkbp:drug_interactions |
limited interactions reported
|
| gptkbp:effective_date |
2017-11-30
|
| gptkbp:feedback |
generally positive
|
| gptkbp:financial_support |
available through Heron Therapeutics
provided by Heron Therapeutics |
| gptkbp:formulation |
injectable
lipid-based |
| gptkbp:funding |
supported by Heron Therapeutics
|
| gptkbp:healthcare |
November 2017
|
| https://www.w3.org/2000/01/rdf-schema#label |
CINVANTI
|
| gptkbp:indication |
prevention of nausea and vomiting associated with emetogenic chemotherapy
|
| gptkbp:ingredients |
aprepitant
|
| gptkbp:invention |
Heron Therapeutics
|
| gptkbp:is_effective_against |
shown to reduce nausea
shown to reduce vomiting |
| gptkbp:manufacturer |
Heron Therapeutics
|
| gptkbp:market |
conducted to assess effectiveness
|
| gptkbp:market_launch |
gptkb:2018
|
| gptkbp:marketed_as |
CINVANTI brand name
|
| gptkbp:marketing_strategy |
focus on oncology centers
|
| gptkbp:mechanism_of_action |
NK1 receptor antagonist
|
| gptkbp:packaging |
vial
single-use vial |
| gptkbp:patient_education |
important for adherence
|
| gptkbp:patient_population |
cancer patients
adults and children 12 years and older used in adult populations |
| gptkbp:pharmacokinetics |
long half-life
rapid distribution |
| gptkbp:price |
varies by provider
|
| gptkbp:provides_guidance_on |
included in NCCN guidelines
recommended in various protocols |
| gptkbp:publication |
published in medical journals
|
| gptkbp:regulatory_compliance |
FDA approved
|
| gptkbp:requires |
available on FDA website
|
| gptkbp:research |
ongoing studies for other indications
|
| gptkbp:research_focus |
improving antiemetic therapy
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:service_frequency |
once before chemotherapy
|
| gptkbp:side_effect |
dizziness
fatigue headache constipation hypersensitivity reactions hypersensitivity reaction monitored post-marketing |
| gptkbp:storage |
refrigerated
store at room temperature |
| gptkbp:supply_chain |
managed by Heron Therapeutics
|
| gptkbp:treatment |
improved quality of life
|
| gptkbp:type_of_insurance |
may be covered by insurance
|
| gptkbp:used_for |
chemotherapy-induced nausea and vomiting
|
| gptkbp:bfsParent |
gptkb:Heron_TP
|
| gptkbp:bfsLayer |
7
|